Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial.
Saved in:
| Title: | Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial. |
|---|---|
| Authors: | Vigneswaran, Hari T.1,2 (AUTHOR) hari.vigneswaran@ki.se, Palsdottir, Thorgerdur1 (AUTHOR), Micoli, Chiara1 (AUTHOR), Tilki, Derya3,4,5 (AUTHOR), Lin, Daniel6 (AUTHOR), Cooperberg, Matthew7 (AUTHOR), Eggener, Scott8 (AUTHOR), Falagario, Ugo Giovanni2 (AUTHOR), Möller, Axel2 (AUTHOR), Aly, Markus2 (AUTHOR), Akre, Olof2 (AUTHOR), Wiklund, Peter2 (AUTHOR), Egevad, Lars9 (AUTHOR), Grönberg, Henrik1 (AUTHOR), Nordström, Tobias1,10 (AUTHOR), Eklund, Martin1 (AUTHOR) |
| Source: | European Urology. Jan2026, Vol. 89 Issue 1, p82-90. 9p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
